argenx Announces European Commission Approval of VYVGART™ (efgartigimod alfa-fcab) for the Treatment of Generalized Myasthenia Gravis

The approval is applicable to all 27 European Union (EU) Member States plus Iceland, Norway and Liechtenstein.